Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
Soleno Therapeutics (NASDAQ:SLNO) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Soleno Therapeutics (NASDAQ:SLNO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
SLNO INVESTOR ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Fraud Investigation
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman